Aiforia Technologies Plc Press release 15 May 2024 at 03:30 pm EEST
Aiforia has been selected to conclude a framework agreement to provide AI solutions to Fimlab Laboratories in Finland to support Diagnostics in pathology.
Fimlab is the largest laboratory company in Finland, mainly providing laboratory services to public healthcare, as well as laboratory training and research. Fimlab's call for tenders sought suppliers of AI models for nine applications and a development platform for AI models. The three best suppliers have been selected for each application and framework agreements for 72 months will be concluded with these suppliers. The value of the procurement for each supplier depends on the number of orders made under the framework agreement.
"We are beyond excited that the Finnish laboratory company Fimlab has chosen to conclude a framework agreement with Aiforia. This proves yet again that our solutions serve the needs of diagnostic laboratories for AI-assisted Pathology workflow," says Jukka Tapaninen, CEO of Aiforia.
Certified Adviser
UB Securities Ltd, tel. +358 9 25 380 225
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more: www.aiforia.com
Back to all blog posts
